MA51625A - Procédé de production de modulateurs de somatostatine - Google Patents

Procédé de production de modulateurs de somatostatine

Info

Publication number: MA51625A
Authority: MA; Morocco
Prior art keywords: production process; somatostatin modulators; somatostatin; modulators; production
Prior art date: 2018-01-17

Application number

MA051625A

Other languages

English (en)

Other versions

MA51625B1 (fr

Inventor

Uttam Dash

Madhukar Kota

Mahmoud Mirmehrabi

Jayachandra P Reddy

Jian Zhao

Yunfei Zhu

Original Assignee

Crinetics Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-01-17

Filing date

2019-01-16

Publication date

2021-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67213594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA51625(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-01-16 Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc

2021-04-21 Publication of MA51625A publication Critical patent/MA51625A/fr

2022-07-29 Publication of MA51625B1 publication Critical patent/MA51625B1/fr

Links

102000005157 Somatostatin Human genes 0.000 title 1
108010056088 Somatostatin Proteins 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
229960000553 somatostatin Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Optical Communication System (AREA)
Eye Examination Apparatus (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Peptides Or Proteins (AREA)

MA51625A 2018-01-17 2019-01-16 Procédé de production de modulateurs de somatostatine MA51625B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862618538P	2018-01-17	2018-01-17
PCT/US2019/013844 WO2019143718A1 (fr)	2018-01-17	2019-01-16	Procédé de production de modulateurs de somatostatine

Publications (2)

Publication Number	Publication Date
MA51625A true MA51625A (fr)	2021-04-21
MA51625B1 MA51625B1 (fr)	2022-07-29

Family

ID=67213594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA51625A MA51625B1 (fr)	2018-01-17	2019-01-16	Procédé de production de modulateurs de somatostatine

Country Status (28)

Country	Link
US (4)	US10464918B2 (fr)
EP (2)	EP4092018A1 (fr)
JP (2)	JP7113900B2 (fr)
KR (1)	KR102462586B1 (fr)
CN (1)	CN111868049B (fr)
AU (1)	AU2019209469B2 (fr)
CA (1)	CA3088658A1 (fr)
CY (1)	CY1125354T1 (fr)
DK (1)	DK3740475T3 (fr)
EA (1)	EA202091559A1 (fr)
ES (1)	ES2923529T3 (fr)
HR (1)	HRP20220852T1 (fr)
HU (1)	HUE059184T2 (fr)
IL (1)	IL276029B2 (fr)
LT (1)	LT3740475T (fr)
MA (1)	MA51625B1 (fr)
MD (1)	MD3740475T2 (fr)
MX (1)	MX2020007586A (fr)
PL (1)	PL3740475T3 (fr)
PT (1)	PT3740475T (fr)
RS (1)	RS63387B1 (fr)
SG (1)	SG11202006838VA (fr)
SI (1)	SI3740475T1 (fr)
SM (1)	SMT202200298T1 (fr)
TW (1)	TWI823891B (fr)
UA (1)	UA127355C2 (fr)
WO (1)	WO2019143718A1 (fr)
ZA (1)	ZA202004497B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL264178B2 (en)	2016-07-14	2024-05-01	Crinetics Pharmaceuticals Inc	Somatostatin modulators and uses thereof
EP3658560A4 (fr)	2017-07-25	2021-01-06	Crinetics Pharmaceuticals, Inc.	Modulateurs de la somatostatine et utilisations de ces derniers
PT3740475T (pt)	2018-01-17	2022-07-18	Crinetics Pharmaceuticals Inc	Processo de produção de moduladores da somatostatina
CA3191084A1 (fr) *	2020-09-09	2022-03-17	Gerald Burke	Formulations d'un modulateur de somatostatine
CN113214050B (zh) *	2021-05-15	2022-07-19	宁夏忠同生物科技有限公司	一种合成2,3,5,6-四氟苯酚的方法
BR112023024465A2 (pt) *	2021-05-25	2024-02-06	Crinetics Pharmaceuticals Inc	Usos de um modulador de somatostatina para o tratamento de doença
WO2023137018A1 (fr) *	2022-01-11	2023-07-20	Crinetics Pharmaceuticals, Inc.	Utilisations d'un modulateur de somatostatine pour le traitement du syndrome carcinoïde
EP4547654A1 (fr)	2022-06-10	2025-05-07	Assia Chemical Industries Ltd.	Formes à l'état solide de paltusotine et leur procédé de préparation
KR20250162795A (ko)	2023-03-28	2025-11-19	크리네틱스 파마슈티칼스, 인크.	간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1035154A (en)	1910-05-16	1912-08-13	Ernest G Clark	Machine for rectifying perforated music and masters.
US1046491A (en)	1910-08-24	1912-12-10	Alfred Randolph	Gas-engine.
FR2802206B1 (fr)	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
CA2468159A1 (fr) *	2001-11-27	2003-06-05	Merck & Co., Inc.	Composes 4-aminoquinoleines
WO2003066055A1 (fr) *	2002-02-04	2003-08-14	F. Hoffmann-La Roche Ag	Derives de quinoline (n) en tant qu'antagonistes du neuropeptide y (npy)
US7767817B2 (en)	2003-09-05	2010-08-03	Binghe Wang	Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja)	2004-07-13	2008-03-06	グラクソ　グループ　リミテッド	抗細菌剤
AU2007309708A1 (en) *	2006-03-13	2008-05-02	Merck Sharp & Dohme Corp.	Somatostatin agonists
GB0818241D0 (en)	2008-10-06	2008-11-12	Cancer Res Technology	Compounds and their use
CA2806332C (fr)	2010-07-30	2017-11-14	Oncotherapy Science, Inc.	Derives de quinoline et inhibiteurs de melk les contenant
RU2637936C2 (ru) *	2011-05-23	2017-12-08	Элан Фармасьютикалз, Инк.	Ингибиторы активности киназы lrrk2
US20140228417A1 (en) *	2011-10-05	2014-08-14	Mapi Pharma Ltd.	Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
WO2014007228A1 (fr)	2012-07-03	2014-01-09	小野薬品工業株式会社	Composé ayant une activité agoniste sur un récepteur de la somatostatine, et leur utilisation à des fins médicales
CN105073729A (zh)	2012-10-16	2015-11-18	詹森药业有限公司	RORγt的苯基连接的喹啉基调节剂
US9643951B2 (en) *	2013-09-30	2017-05-09	Ono Pharmaceutical Co., Ltd.	Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
JO3805B1 (ar)	2013-10-10	2021-01-31	Araxes Pharma Llc	مثبطات كراس جي12سي
WO2016049568A1 (fr)	2014-09-25	2016-03-31	Araxes Pharma Llc	Méthodes et compositions permettant l'inhibition de la ras
EP3317278B1 (fr) *	2015-07-01	2021-04-14	Crinetics Pharmaceuticals, Inc.	Modulateurs de somatostatine et leurs utilisations
US9957267B2 (en)	2015-07-01	2018-05-01	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
IL264178B2 (en)	2016-07-14	2024-05-01	Crinetics Pharmaceuticals Inc	Somatostatin modulators and uses thereof
PT3740475T (pt)	2018-01-17	2022-07-18	Crinetics Pharmaceuticals Inc	Processo de produção de moduladores da somatostatina

2019
- 2019-01-16 PT PT197407331T patent/PT3740475T/pt unknown
- 2019-01-16 WO PCT/US2019/013844 patent/WO2019143718A1/fr not_active Ceased
- 2019-01-16 PL PL19740733.1T patent/PL3740475T3/pl unknown
- 2019-01-16 MA MA51625A patent/MA51625B1/fr unknown
- 2019-01-16 SI SI201930277T patent/SI3740475T1/sl unknown
- 2019-01-16 MD MDE20201200T patent/MD3740475T2/ro not_active IP Right Cessation
- 2019-01-16 SM SM20220298T patent/SMT202200298T1/it unknown
- 2019-01-16 JP JP2020538675A patent/JP7113900B2/ja active Active
- 2019-01-16 ES ES19740733T patent/ES2923529T3/es active Active
- 2019-01-16 SG SG11202006838VA patent/SG11202006838VA/en unknown
- 2019-01-16 HU HUE19740733A patent/HUE059184T2/hu unknown
- 2019-01-16 MX MX2020007586A patent/MX2020007586A/es unknown
- 2019-01-16 UA UAA202004625A patent/UA127355C2/uk unknown
- 2019-01-16 CA CA3088658A patent/CA3088658A1/fr active Pending
- 2019-01-16 DK DK19740733.1T patent/DK3740475T3/da active
- 2019-01-16 AU AU2019209469A patent/AU2019209469B2/en active Active
- 2019-01-16 US US16/249,729 patent/US10464918B2/en active Active
- 2019-01-16 HR HRP20220852TT patent/HRP20220852T1/hr unknown
- 2019-01-16 EP EP22168295.8A patent/EP4092018A1/fr not_active Withdrawn
- 2019-01-16 KR KR1020207023546A patent/KR102462586B1/ko active Active
- 2019-01-16 RS RS20220660A patent/RS63387B1/sr unknown
- 2019-01-16 CN CN201980019970.7A patent/CN111868049B/zh active Active
- 2019-01-16 IL IL276029A patent/IL276029B2/en unknown
- 2019-01-16 EA EA202091559A patent/EA202091559A1/ru unknown
- 2019-01-16 EP EP19740733.1A patent/EP3740475B1/fr active Active
- 2019-01-16 LT LTEPPCT/US2019/013844T patent/LT3740475T/lt unknown
- 2019-01-17 TW TW108101800A patent/TWI823891B/zh active
- 2019-10-03 US US16/592,595 patent/US10889561B2/en active Active
2020
- 2020-07-21 ZA ZA2020/04497A patent/ZA202004497B/en unknown
- 2020-12-09 US US17/116,728 patent/US20210087165A1/en not_active Abandoned
2022
- 2022-07-12 CY CY20221100472T patent/CY1125354T1/el unknown
- 2022-07-26 JP JP2022118926A patent/JP2022166016A/ja active Pending
2024
- 2024-02-26 US US18/587,187 patent/US20240376067A1/en active Pending

Also Published As

Publication number	Publication date
US20210087165A1 (en)	2021-03-25
TWI823891B (zh)	2023-12-01
AU2019209469B2 (en)	2022-09-08
RS63387B1 (sr)	2022-08-31
US20240376067A1 (en)	2024-11-14
CN111868049A (zh)	2020-10-30
JP7113900B2 (ja)	2022-08-05
SI3740475T1 (sl)	2022-09-30
EP3740475A4 (fr)	2021-06-09
MD3740475T2 (ro)	2022-09-30
CN111868049B (zh)	2023-06-30
PL3740475T3 (pl)	2022-08-16
SMT202200298T1 (it)	2022-09-14
WO2019143718A1 (fr)	2019-07-25
UA127355C2 (uk)	2023-07-26
US20190218202A1 (en)	2019-07-18
JP2022166016A (ja)	2022-11-01
KR20200101470A (ko)	2020-08-27
KR102462586B1 (ko)	2022-11-03
MA51625B1 (fr)	2022-07-29
ES2923529T3 (es)	2022-09-28
BR112020014462A2 (pt)	2020-12-01
IL276029B1 (en)	2024-03-01
MX2020007586A (es)	2020-09-03
US10889561B2 (en)	2021-01-12
DK3740475T3 (da)	2022-07-11
US10464918B2 (en)	2019-11-05
CA3088658A1 (fr)	2019-07-25
EP3740475A1 (fr)	2020-11-25
PT3740475T (pt)	2022-07-18
CY1125354T1 (el)	2025-05-09
JP2021511303A (ja)	2021-05-06
ZA202004497B (en)	2023-01-25
AU2019209469A1 (en)	2020-08-06
EP4092018A1 (fr)	2022-11-23
EA202091559A1 (ru)	2020-12-15
EP3740475B1 (fr)	2022-04-20
IL276029A (en)	2020-08-31
HUE059184T2 (hu)	2022-10-28
TW201934551A (zh)	2019-09-01
SG11202006838VA (en)	2020-08-28
IL276029B2 (en)	2024-07-01
LT3740475T (lt)	2022-08-25
US20200048219A1 (en)	2020-02-13
HRP20220852T1 (hr)	2022-10-14

Publication	Publication Date	Title
EP3740475A4 (fr)	2021-06-09	Procédé de production de modulateurs de somatostatine
EP3909962A4 (fr)	2022-12-28	Procédé de production de l-glufosinate
EP3763747A4 (fr)	2021-12-01	Procédé de production de fluoropolymère
EP3842539A4 (fr)	2022-01-19	Procédé de synthèse de lacto-n-biose
EP3613404A4 (fr)	2021-03-03	Procédé de production de film
EP3840852A4 (fr)	2022-05-18	Procédé de production de cannabinoïdes
EP3747624A4 (fr)	2021-02-17	Procédé de production de structure
MA48798A (fr)	2020-04-08	Procédé de production d'ozanimod
EP3578536A4 (fr)	2021-05-26	Procédé de production d'hydrocarbure fluorohalogéné
EP3845523A4 (fr)	2021-07-07	Procédé de synthèse de cariprazine
EP3626804A4 (fr)	2020-05-27	Procédé de purification de raffinat-2
EP3820169A4 (fr)	2021-12-22	Procédé de configuration de paramètres
EP3828252A4 (fr)	2022-04-20	Procédé de production de biocarburant
EP3704551A4 (fr)	2021-08-18	Procédé de production distribuée
EP3831804A4 (fr)	2022-04-20	Procédé de production de 1-acyloxy-2-méthyl-2-propène
EP3838465A4 (fr)	2021-12-01	Procédé de production de structure assemblée
EP3689852A4 (fr)	2021-06-09	Procédé de production de dihydroxyindoles
EP3705473A4 (fr)	2021-07-07	Procédé de production de dihydroxyindoles
EP3760609A4 (fr)	2021-04-21	Procédé de production de xylylènediamine
EP3848344A4 (fr)	2022-06-22	Procédé de production de pipérylène
EP3848198A4 (fr)	2022-08-10	Procédé de production de stratifié
EP3819294A4 (fr)	2022-03-16	Procédé de production de gadobutrol
EP4074750A4 (fr)	2023-01-11	Procédé de production de polyamide
EP4043936A4 (fr)	2023-11-01	Procédé de câblage
EP4000750A4 (fr)	2023-07-19	Procédé de revêtement